NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03585296,A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis,https://clinicaltrials.gov/study/NCT03585296,,COMPLETED,"This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD). Subjects will be required to apply ATI-502 study medication to their identified AD treatment areas. All subjects will be required to complete a safety follow up visit 4 weeks post last study medication application",YES,Atopic Dermatitis,DRUG: ATI-502,"Number of Subjects withTreatment-Emergent Adverse Events (Safety and Tolerability), Treatment emergent adverse events (TEAEs)graded on a 3 point scale of mild, moderate or severe, 8 weeks",,,"Aclaris Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,22,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,ATI-502-AD-201,2018-07-10,2019-04-25,2019-04-25,2018-07-13,2020-01-22,2020-02-17,"Aclaris Investigational Site, Encinitas, California, 92024, United States|Aclaris Investigator Site, San Diego, California, 92123, United States|Aclaris Investigator Site, Fridley, Minnesota, 55432, United States|Aclaris Investigational Site, Bexley, Ohio, 43209, United States|Aclaris Investigational Site, Portland, Oregon, 97223, United States|Aclaris Investigator Site, Austin, Texas, 78759, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/96/NCT03585296/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/96/NCT03585296/SAP_001.pdf"
